as 09-06-2024 4:00pm EST
Stocks
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 1.8B | IPO Year: | 2023 |
Target Price: | $81.33 | AVG Volume (30 days): | 525.6K |
Analyst Decision: | Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.22 | EPS Growth: | N/A |
52 Week Low/High: | $26.61 - $75.02 | Next Earning Date: | 08-08-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
GPCR Breaking Stock News: Dive into GPCR Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
GlobeNewswire
11 days ago
GlobeNewswire
12 days ago
Simply Wall St.
21 days ago
Barrons.com
a month ago
Barrons.com
a month ago
Insider Monkey
a month ago
GlobeNewswire
a month ago
The information presented on this page, "GPCR Structure Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.